SK Chemicals to Collaborate with Canadian Cyclica on AI Drug Development

SK Chemicals Pangyo Headquarters Exterior (Photo by SK Chemicals)

[Asia Economy Reporter Chunhee Lee] SK Chemicals announced on the 14th that it has signed a 'joint AI drug development research' agreement with Cyclica, a Canadian artificial intelligence (AI) drug development platform company.

Cyclica is an AI-based drug development platform company that independently holds CNS (central nervous system) disease, oncology, and autoimmune disease target pipelines. It possesses AI-based candidate discovery platforms 'Ligand Design' and 'Ligand Express,' which can screen candidate substances by considering pharmacological, physicochemical, and in vivo kinetic properties of drug targets and their binding candidates.

Through this collaboration, Cyclica will utilize its proprietary drug development platform to discover drug candidates in disease areas of mutual interest, while SK Chemicals will be responsible for preclinical, clinical development, and global commercialization of the candidates discovered by Cyclica.

Vern De Biasi, Chief Partnership Officer (CPO) of Cyclica, said, "We are pleased to collaborate with SK Chemicals," adding, "This partnership will leverage the strengths of both companies to develop new drugs for patients and improve human health." Kim Yunho, Head of Pharma Business at SK Chemicals, also stated, "Cyclica's technology is expected to assist in developing drug candidates for challenging biological targets," and "Combining SK Chemicals' organizational strength and development experience with Cyclica's expertise and know-how will create synergy."

This content was produced with the assistance of AI translation services.